Panexin BMM Panexin BMM is a chemically defined serum substitute for the cultivation of macrophages from mouse bone marrow (murine bone marrow derived macrophages, BMM) under serum- free conditions. The ready-to-use sterile solution in a final concentration of 5 % is added to the basal medium RPMI 1640, supplemented with 50 μM Mercaptoethanol and 2 ng/ml GM-CSF mur. rec. Description Size Product number Panexin BMM 100 ml P04-951SA2    Composition Panexin BMM contains purified proteins, lipids, salts, amino acids, trace elements, attachment factors and hormones in an optimized formulation. It contains no growth factors, undefined hydrolysates or lysates (e. g. Peptones).    Suitability Panexin BMM has been developed for the generation of murine macrophages from bone marrow under serum- free conditions. This achieves standardized conditions and reproducible results.    Special advantages Panexin BMM allows the generation of murine macrophages from bone marrow under standardized serum- free conditions. The results will be more comparable, as undefined components – like in serum-containing cultures – are eliminated. In Panexin BMM matured macrophages will show excellent attachment capabilities.    References by cell lines Bone marrow derived macrophages • Stolt et al., J Immunol. 2016 Aug 1;197(3):834-46. http://www.jimmunol.org/content/197/3/834.short • Hommes et al., Am J Respir Cell Mol Biol. 2015 Nov;53(5):647-55 http://www.atsjournals.org/doi/pdf/10.1165/rcmb.2014-0485OC • Hof et al., Infect Immun. 2014 May; 82(5): 2006–2015 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993457/ • Depke et al., Journal of Proteomics Volume 103, 30 May 2014, Pages 72–86 http://www.sciencedirect.com/science/article/pii/S1874391914001493 • Schramm et al., Eur. J. Immunol. 2014. 44: 728–741. http://onlinelibrary.wiley.com/doi/10.1002/eji.201343940/full • Bast et al., LoS Pathog 10(3): e1003986. doi:10.1371/journal.ppat.1003986. http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003986 • Koh et al., PLoS Negl Trop Dis. 2013 Oct; 7(10): e2500 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798430/ • Farinacci et al., Vaccine. 2012 Dec 14;30(52):7608-14 https://www.ncbi.nlm.nih.gov/pubmed/23088886 • Erttmann et al., Free Radic Biol Med. 2011 Aug 1;51(3):626-40 http://www.sciencedirect.com/science/article/pii/S0891584911003248 • Norville et al., Microbiology. 2011 Sep;157(Pt 9):2629-38 https://www.ncbi.nlm.nih.gov/pubmed/21680634 • Breitbach et al., BMC Immunol. 2011; 12: 20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072354/ • Bast et al., Toxicol In Vitro. 2010 Mar;24(2):686-94. https://www.ncbi.nlm.nih.gov/pubmed/20869433 • Eske et al., J Immunol Methods. 2009 Mar 15;342(1-2):13-9. https://www.ncbi.nlm.nih.gov/pubmed/19133267 • Breitbach et al., Infect Immun. 2009 Apr; 77(4): 1589–1595 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663179/ • Traeger et al., Infect Immun. 2008 Nov; 76(11): 5285–5293 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2573314/ HEK • Lisa Rauschenberger, Dissertation „Strukturelle und funktionelle Charakterisierung von Exosomen aus Prostatakarzinomzellen“, 2016. http://d-nb.info/111106475X/34 • Into et al., Mol Cell Biol. 2008 Feb; 28(4): 1338–1347. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2258749/ And many more!!!